MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Lymphoma Diagnosis and Treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,251 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,251 works in the cohort · of 4,299,418page 50 of 66

Labels cover 5 of 3,251 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,251 of 3,251 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan (90Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma
Nancy Pennell, Matthew C. Cheung, Lisa K. Hicks, Eugenia Piliotis, Kevin Imrie, Rena Buckstein +5 more
2011· article· en· Blood· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Small Lymphocytic Lymphoma
Jori Hardin
2024· article· en· Journal of Cutaneous Medicine and Surgery· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
venueno affunlabeled
Dr. Griffiths et al reply
Jo Leadbetter, Hedley Griffiths
2022· letter· fr· The Journal of Rheumatology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About